Cheyenne, United States
TecMed, Inc., founded in 1995, operates as a privately held intellectual property company specializing in medical devices. Headquartered in the United States, TecMed has focused its efforts on developing and licensing cutting-edge IP.
At the core of TecMed's offerings is their patented Sentinel Real-Time Continuous Glucose Monitoring (RT-CGM) platform, which provides real-time, cost-effective, and highly accurate glucose measurements with an industry-leading accuracy margin of +/-6%. Unlike traditional methods, TecMed's technology uses direct optical measurements instead of relying on enzymatic reactions and predictive algorithms, significantly reducing the need for manual interventions like finger pricks.
While TecMed has not reported investments since its seed round in 2013, its focus on forming strategic business relationships makes it a promising candidate for investors in the Biotechnology and Health Care industries. The company's strong management team, with extensive industry experience, further solidifies its potential for long-term success.
